Clinical Evaluation of Silk'n Glide for Face

1. Presence of unwanted hairs on the face
2. Skin Type I to IV (Fitzpatrick)
3. Adults older than 21 years of age but not more than 60 years of age.
4. Must be either post-menopausal or surgically steri-lized, or using a medically acceptable form of birth control (i.e., oral contraceptives, IUD, contraceptive implant, barrier methods with spermicide or absti-nence).
5. Informed consent agreement by the subject.
6. Willingness to follow the treatment schedule and post treatment care.

Exclusion Criteria:

1. Malignant or pre-malignant pigmented lesions in the area to be treated.
2. Scarring or infection of the area to be treated.
3. Known photosensitivity.
4. Pregnancy or lactating
5. Subjects with Diabetes (Type I or II).
6. Presence of a suntan in the area to be treated.
7. Use of medication known to induce photosensitivity.
8. Subject is on anticoagulative medication or throm-boembolic condition.
9. Subjects with a pacemaker or internal defibrillator.
10. Use of NSAIDS two weeks prior to, and two weeks following the treatment.
11. Subjects that use waxing or other methods of photo-epilation 3 months prior to treatment.
12. Subjects that have been exposed to strong sunlight or an artificial tanning machine during the past 4 weeks
13. Subjects wearing a tattoo or permanent makeup on the area to be treated
14. Subjects with dark brown or black spots, such as large freckles, birth marks, moles or warts on the area to be treated
15. Subjects with Eczema, psoriasis, lesions, open wounds or active infections, such as cold sores in the area to be treated
16. Subjects with history of keloidal scar formation
17. Subjects with history of herpes outbreaks in the area of treatment, unless you have consulted your physician and received preventative treatment before using GlideTM
18. Subjects with epilepsy
19. Subjects using incontinence device, insulin pump, other active devices [NB: Protocol excludes pace-makers and internal defibrillators.]
20. Subjects with a history of skin cancer or areas of po-tential skin malignancies
21. Subjects who have received radiation therapy or chemotherapy treatments within the past 3 months